Vivimed Labs shining after USFDA inspection

The inspection of Vivimed Labs’ FDF facility in Alathur was completed by the US Food and Drug Administration (USFDA). The audit was conducted during the last week of November 2016 and concluded on November 28. All the manufacturing plants of the company focusing on the regulated markets have been inspected with a favourable outcome over the last two years.

Vivimed Labs obtained ANDA approval for Metronidazole and the same has been commercialised. During November 2016, the company acquired ANDA of Zolpidem and the file transfer has successfully been completed. It is expected to be commercialised by Q4FY17. Vivimed Labs is on track of its filing targets and has successfully completed 3 ANDA filings during FY17 and expects one more filing to be completed by Q4FY17. These products provide vertical integration with the in-house APIs.

The share price of Vivimed Labs increased 16.3 per cent on the bourses in early trades and was trading at Rs 102.85 on intraday basis. On the BSE, there was spurt in the volumes of the company’s traded shares by over 2.56 times.